Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).

Bergmeijer TO, Reny JL, Pakyz RE, Gong L, Lewis JP, Kim EY, Aradi D, Fernandez-Cadenas I, Horenstein RB, Lee MTM, Whaley RM, Montaner J, Gensini GF, Cleator JH, Chang K, Holmvang L, Hochholzer W, Roden DM, Winter S, Altman RB, Alexopoulos D, Kim HS, Déry JP, Gawaz M, Bliden K, Valgimigli M, Marcucci R, Campo G, Schaeffeler E, Dridi NP, Wen MS, Shin JG, Simon T, Fontana P, Giusti B, Geisler T, Kubo M, Trenk D, Siller-Matula JM, Ten Berg JM, Gurbel PA, Hulot JS, Mitchell BD, Schwab M, Ritchie MD, Klein TE, Shuldiner AR; ICPC Investigators.

Am Heart J. 2018 Apr;198:152-159. doi: 10.1016/j.ahj.2017.12.010. Epub 2017 Dec 17.

PMID:
29653637
2.

The N54-αs Mutant Has Decreased Affinity for βγ and Suggests a Mechanism for Coupling Heterotrimeric G Protein Nucleotide Exchange with Subunit Dissociation.

Cleator JH, Wells CA, Dingus J, Kurtz DT, Hildebrandt JD.

J Pharmacol Exp Ther. 2018 May;365(2):219-225. doi: 10.1124/jpet.117.245779. Epub 2018 Feb 28.

PMID:
29491039
3.

A comparative study of different methods for automatic identification of clopidogrel-induced bleedings in electronic health records.

Lee HJ, Jiang M, Wu Y, Shaffer CM, Cleator JH, Friedman EA, Lewis JP, Roden DM, Denny J, Xu H.

AMIA Jt Summits Transl Sci Proc. 2017 Jul 26;2017:185-192. eCollection 2017.

4.

Species-specific effects of neuregulin-1β (cimaglermin alfa) on glucose handling in animal models and humans with heart failure.

Huang Z, Sawyer DB, Troy EL, McEwen C, Cleator JH, Murphy A, Caggiano AO, Eisen A, Parry TJ.

Toxicol Appl Pharmacol. 2017 Oct 1;332:92-99. doi: 10.1016/j.taap.2017.08.001. Epub 2017 Aug 2.

5.

Physician response to implementation of genotype-tailored antiplatelet therapy.

Peterson JF, Field JR, Unertl KM, Schildcrout JS, Johnson DC, Shi Y, Danciu I, Cleator JH, Pulley JM, McPherson JA, Denny JC, Laposata M, Roden DM, Johnson KB.

Clin Pharmacol Ther. 2016 Jul;100(1):67-74. doi: 10.1002/cpt.331. Epub 2016 Feb 17.

6.

Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention.

Friedman EA, Texeira L, Delaney J, Weeke PE, Lynch DR Jr, Kasasbeh E, Song Y, Harrell FE Jr, Denny JC, Hamm HE, Roden DM, Cleator JH.

J Thromb Thrombolysis. 2016 May;41(4):656-62. doi: 10.1007/s11239-015-1285-4.

PMID:
26446588
7.

Anti-remodeling and anti-fibrotic effects of the neuregulin-1β glial growth factor 2 in a large animal model of heart failure.

Galindo CL, Kasasbeh E, Murphy A, Ryzhov S, Lenihan S, Ahmad FA, Williams P, Nunnally A, Adcock J, Song Y, Harrell FE, Tran TL, Parry TJ, Iaci J, Ganguly A, Feoktistov I, Stephenson MK, Caggiano AO, Sawyer DB, Cleator JH.

J Am Heart Assoc. 2014 Oct 23;3(5):e000773. doi: 10.1161/JAHA.113.000773. Erratum in: J Am Heart Assoc. 2015 Jan;4(1):e000528.

8.

Racial differences in resistance to P2Y12 receptor antagonists in type 2 diabetic subjects.

Cleator JH, Duvernay MT, Holinstat M, Colowick NE, Hudson WJ, Song Y, Harrell FE, Hamm HE.

J Pharmacol Exp Ther. 2014 Oct;351(1):33-43. doi: 10.1124/jpet.114.215616. Epub 2014 Jul 22.

9.

Learning curve in transradial cardiac catheterization: procedure-related parameters stratified by operators' transradial volume.

Kasasbeh ES, Parvez B, Huang RL, Hasselblad MM, Glazer MD, Salloum JG, Cleator JH, Zhao DX.

J Invasive Cardiol. 2012 Nov;24(11):599-604.

10.

Dichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation.

Holinstat M, Colowick NE, Hudson WJ, Blakemore D, Chen Q, Hamm HE, Cleator JH.

J Thromb Thrombolysis. 2013 Feb;35(2):209-22. doi: 10.1007/s11239-012-0812-9.

11.

Predicting clopidogrel response using DNA samples linked to an electronic health record.

Delaney JT, Ramirez AH, Bowton E, Pulley JM, Basford MA, Schildcrout JS, Shi Y, Zink R, Oetjens M, Xu H, Cleator JH, Jahangir E, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC.

Clin Pharmacol Ther. 2012 Feb;91(2):257-63. doi: 10.1038/clpt.2011.221. Epub 2011 Dec 21.

12.

Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room.

Zhao DX, Leacche M, Balaguer JM, Boudoulas KD, Damp JA, Greelish JP, Byrne JG; Writing Group of the Cardiac Surgery, Cardiac Anesthesiology, and Interventional Cardiology Groups at the Vanderbilt Heart and Vascular Institute, Ahmad RM, Ball SK, Cleator JH, Deegan RJ, Eagle SS, Fong PP, Fredi JL, Hoff SJ, Jennings HS 3rd, McPherson JA, Piana RN, Pretorius M, Robbins MA, Slosky DA, Thompson A.

J Am Coll Cardiol. 2009 Jan 20;53(3):232-41. doi: 10.1016/j.jacc.2008.10.011.

13.

Clinical implications of the contrasting effects of in vivo thrombin receptor activation (protease-activated receptor type 1) on the human vasculature.

Cleator JH, Vaughan DE.

J Am Coll Cardiol. 2008 May 6;51(18):1757-9. doi: 10.1016/j.jacc.2008.01.037. No abstract available.

14.
15.

G Protein betagamma dimer formation: Gbeta and Ggamma differentially determine efficiency of in vitro dimer formation.

Dingus J, Wells CA, Campbell L, Cleator JH, Robinson K, Hildebrandt JD.

Biochemistry. 2005 Sep 6;44(35):11882-90.

PMID:
16128590
16.

Thrombin modulates the expression of a set of genes including thrombospondin-1 in human microvascular endothelial cells.

McLaughlin JN, Mazzoni MR, Cleator JH, Earls L, Perdigoto AL, Brooks JD, Muldowney JA 3rd, Vaughan DE, Hamm HE.

J Biol Chem. 2005 Jun 10;280(23):22172-80. Epub 2005 Apr 7.

18.

Identification of a region in G protein gamma subunits conserved across species but hypervariable among subunit isoforms.

Cook LA, Schey KL, Cleator JH, Wilcox MD, Dingus J, Hildebrandt JD.

Protein Sci. 2001 Dec;10(12):2548-55.

19.

Supplemental Content

Loading ...
Support Center